Literature DB >> 29959759

Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.

Chi Nguyen1, David R Lairson2, Michael D Swartz3, Xianglin L Du4.   

Abstract

OBJECTIVE: This retrospective cohort study aims to examine the receipt, timing to initiation, and duration of androgen deprivation therapy (ADT) in men with prostate cancer by race/ethnicity, socioeconomic status, and geographic location.
METHODS: The study population are patients from Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, who were 66 years or older and newly diagnosed with stage III and IV prostate cancer in 1992-2009 and underwent radiation therapy, where ADT was proven to be highly beneficial and its use was considered as most appropriate (n = 12,170). We use logistic regression to examine the receipt of ADT and linear regression to study factors associated with time to ADT initiation while controlling for baseline characteristics.
RESULTS: Overall, 77% of eligible patients received at least one form of ADT in combination with radiation therapy, of which 12% underwent orchiectomy and the rest received ADT, and 77.2% of non-Hispanic white and 80.7% of Hispanic patients received ADT compared to 73.8% of non-Hispanic black. After adjustment for demographic and tumor characteristics, black men and men of other races are less likely to receive ADT compared to white counterparts (OR = 0.64 and 0.74, respectively). The median time from cancer diagnosis to ADT initiation is 2 months. Once initiated, men received a median of seven drug injections. After controlling for covariates, race/ethnicity and geographic location (SEER areas) are associated with early initiation of therapy. White, Hispanic men and men living in the South initiate ADT earlier.
CONCLUSION: Significant racial disparities exist in the receipt and use of this highly beneficial therapy, and there are geographic variations in the utilization of this therapy.

Entities:  

Keywords:  Androgen deprivation therapy; Disparities; Prostate cancer; Race/ethnicity; Treatment

Mesh:

Substances:

Year:  2018        PMID: 29959759     DOI: 10.1007/s40615-018-0508-8

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  26 in total

1.  The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment.

Authors:  C J Mettlin; G P Murphy; M P Cunningham; H R Menck
Journal:  Cancer       Date:  1997-10-01       Impact factor: 6.860

2.  Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.

Authors:  L Holmes; W Chan; Z Jiang; X L Du
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-05-08       Impact factor: 5.554

3.  Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Authors:  Nicolas Mottet; Jean Van Damme; Salim Loulidi; Christoph Russel; Armin Leitenberger; Johannes M Wolff
Journal:  BJU Int       Date:  2012-04-13       Impact factor: 5.588

4.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Authors:  Michel Bolla; Geertjan Van Tienhoven; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Ignace Billiet; José Lopez Torecilla; Raphael Pfeffer; Carmel Lino Cutajar; Theodore Van der Kwast; Laurence Collette
Journal:  Lancet Oncol       Date:  2010-10-07       Impact factor: 41.316

5.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

Review 6.  Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma.

Authors:  Domenico Prezioso; Fabrizio Iacono; Giuseppe Romeo; Antonio Ruffo; Nicola Russo; Ester Illiano
Journal:  World J Urol       Date:  2013-08-08       Impact factor: 4.226

7.  Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Authors:  Richard M Hoffman; Linda C Harlan; Carrie N Klabunde; Frank D Gilliland; Robert A Stephenson; William C Hunt; Arnold L Potosky
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

8.  Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients.

Authors:  Jinan Liu; Lizheng Shi; Oliver Sartor; Richard Culbertson
Journal:  Onco Targets Ther       Date:  2013-06-17       Impact factor: 4.147

Review 9.  Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review.

Authors:  André D Sasse; Elisa Sasse; Albertina M Carvalho; Ligia T Macedo
Journal:  BMC Cancer       Date:  2012-02-02       Impact factor: 4.430

Review 10.  Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer.

Authors:  Tomasz Golabek; Jonathan Belsey; Tomasz Drewa; Anna Kołodziej; Iwona Skoneczna; Piotr Milecki; Jakub Dobruch; Marcin Słojewski; Piotr L Chłosta
Journal:  Cent European J Urol       Date:  2016-06-20
View more
  2 in total

Review 1.  The Impact of African Ancestry on Prostate Cancer Disparities in the Era of Precision Medicine.

Authors:  Deyana D Lewis; Cheryl D Cropp
Journal:  Genes (Basel)       Date:  2020-12-08       Impact factor: 4.096

Review 2.  The Intersection of Rural Residence and Minority Race/Ethnicity in Cancer Disparities in the United States.

Authors:  Whitney E Zahnd; Cathryn Murphy; Marie Knoll; Gabriel A Benavidez; Kelsey R Day; Radhika Ranganathan; Parthenia Luke; Anja Zgodic; Kewei Shi; Melinda A Merrell; Elizabeth L Crouch; Heather M Brandt; Jan M Eberth
Journal:  Int J Environ Res Public Health       Date:  2021-02-03       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.